The Life Sciences team advised the underwriting syndicate Goldman Sachs Citigroup and H.C. Wainwright Co. in connection with the closing of DBV Technologies S.A. NASDAQ DBVT approximately 81 million follow-on offering including the full exercise of the underwriters option to purchase additional shares. The offering consisted of 2447500 ordinary shares in the form of 4895000 American Depositary Shares sold in the United States Canada and certain other countries outside Europe at a public offering price of 6.75 per ADS and 3552500 ordinary shares sold in Europe in a concurrent private placement at a price of 12.02 per ordinary share. Based in France DBV is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The companys therapeutic approach is based on epicutaneous immunotherapy or EPIT their proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. DBV are advancing this unique technology to treat patients including infants and children suffering from severe food allergies.
🔍 Key Information
📄
Tender Reference No.
443825005
📅
Publication Date
27 Apr 2019
🌐
Sector
Banking, Finance, Insurance and Securities (BFIS)
📝
Notice Type
News
📍
Location
United states
📁
Documents & Downloads
No documents found
🏷️ CPV
No CPV found
Need help with this bid?
Our bid experts can help you find, evaluate & win more tenders.